Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
| ▸ | FLT4 | P35916 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696276 | 0.89 | TRPV1 (0.42) | TRPV1FLT1FLT4KDRSMPD1 | |
| SCHEMBL22925705 | 0.85 | FLT1 (0.46) | TRPV1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL22925873 | 0.83 | IMPDH2 (0.45) | TRPV1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL22926050 | 0.80 | NPSR1 (0.39) | TRPV1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL28733678 | 0.80 | NPSR1 (0.39) | TRPV1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL29620970 | 0.80 | NPSR1 (0.39) | TRPV1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL31756267 | 0.80 | TRPV1 (0.47) | TRPV1FLT1KDRKITVCP | |
| SCHEMBL28733676 | 0.79 | TRPV1 (0.41) | TRPV1FLT1FLT4KDRSMPD1 | |
| SCHEMBL22926080 | 0.78 | IMPDH2 (0.43) | TRPV1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL29696304 | 0.78 | IMPDH2 (0.43) | TRPV1FLT1FLT4KDRIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001870-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001870-A1 | INHIBITOR COMPOUNDS | CES1, NCEH1, NR1H2 | TRPV1 3641/4885FLT1 2182/4885FLT4 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.